Transgenic Vero-CD4/CCR5 cell line
US10279027B2 · kind B2 · utility
0Cited by
1References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 6, 2017 |
| Grant date | May 7, 2019 |
| Priority date | — |
| Expiry date | Apr 6, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2810/6081
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present relation relates to a transgenic Vero cell line expressing CD4 and CCR5. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.